Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism

Z Laron; B Klinger; L T Jensen; B Erster

Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism

Z Laron, B Klinger, L T Jensen, B Erster

Department of Clinical Medicine

58 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of this investigation was to evaluate the effectiveness of short-term administration of recombinant biosynthetic IGF-I on patients with an hereditary inability to generate this hormone.

DESIGN AND PATIENTS: Ten patients with Laron type dwarfism (LTD) (4 males, six females) aged 3 1/2 to 37 3/4 years were submitted to seven daily s.c. injections of recombinant IGF-I in doses of 120 or 150 micrograms/kg/day.

MEASUREMENTS: Blood samples were drawn before, after three and seven injections, and one week after stopping the trial.

RESULTS: The main biochemical and hormonal changes registered were (mean +/- SD): a marked rise in serum type III procollagen (PIIINP) from 4.2 +/- 0.9 to 7.3 +/- 2 micrograms/l (P less than 0.0003) and decrease in the following blood components: plasma hGH from 32.51 +/- 43.77 to 4.02 +/- 2.48 mU/l (P less than 0.001), serum cholesterol from 5.9 +/- 1 to 5.7 +/- 0.8 mmol/l (P less than 0.04), serum SGOT from 28.9 +/- 11.6 to 15.5 +/- 7.6 U/l (P less than 0.01) and serum LDH from 286 +/- 88 to 222 +/- 37 U/l (P less than 0.0005). The response of plasma insulin was variable, decreasing in seven of ten and increasing in three. Some of these effects were transitory, and were found after 3 days therapy but afterwards decreased (insulin, cholesterol and liver tests), others persisted throughout the whole treatment period (hGH, PIINP).

CONCLUSIONS: IGF-I mimics the biochemical and hormonal changes described after administration of hGH. The administration of IGF-I in patients with Laron type dwarfism is devoid of side-effects and warrants assessment in long-term studies.

Original language	English
Journal	Clinical Endocrinology
Volume	35
Issue number	2
Pages (from-to)	145-50
Number of pages	6
ISSN	0300-0664
Publication status	Published - Aug 1991

Keywords

Adolescent
Adult
Aspartate Aminotransferases
Child
Child, Preschool
Cholesterol
Dwarfism
Female
Growth Hormone
Humans
Insulin-Like Growth Factor I
L-Lactate Dehydrogenase
Male
Peptide Fragments
Procollagen
Receptors, Somatotropin
Recombinant Proteins
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Cite this

@article{5e7c2feae7bc4df1b143214c284ec2a1,

title = "Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism",

abstract = "OBJECTIVE: The purpose of this investigation was to evaluate the effectiveness of short-term administration of recombinant biosynthetic IGF-I on patients with an hereditary inability to generate this hormone.DESIGN AND PATIENTS: Ten patients with Laron type dwarfism (LTD) (4 males, six females) aged 3 1/2 to 37 3/4 years were submitted to seven daily s.c. injections of recombinant IGF-I in doses of 120 or 150 micrograms/kg/day.MEASUREMENTS: Blood samples were drawn before, after three and seven injections, and one week after stopping the trial.RESULTS: The main biochemical and hormonal changes registered were (mean +/- SD): a marked rise in serum type III procollagen (PIIINP) from 4.2 +/- 0.9 to 7.3 +/- 2 micrograms/l (P less than 0.0003) and decrease in the following blood components: plasma hGH from 32.51 +/- 43.77 to 4.02 +/- 2.48 mU/l (P less than 0.001), serum cholesterol from 5.9 +/- 1 to 5.7 +/- 0.8 mmol/l (P less than 0.04), serum SGOT from 28.9 +/- 11.6 to 15.5 +/- 7.6 U/l (P less than 0.01) and serum LDH from 286 +/- 88 to 222 +/- 37 U/l (P less than 0.0005). The response of plasma insulin was variable, decreasing in seven of ten and increasing in three. Some of these effects were transitory, and were found after 3 days therapy but afterwards decreased (insulin, cholesterol and liver tests), others persisted throughout the whole treatment period (hGH, PIINP).CONCLUSIONS: IGF-I mimics the biochemical and hormonal changes described after administration of hGH. The administration of IGF-I in patients with Laron type dwarfism is devoid of side-effects and warrants assessment in long-term studies.",

keywords = "Adolescent, Adult, Aspartate Aminotransferases, Child, Child, Preschool, Cholesterol, Dwarfism, Female, Growth Hormone, Humans, Insulin-Like Growth Factor I, L-Lactate Dehydrogenase, Male, Peptide Fragments, Procollagen, Receptors, Somatotropin, Recombinant Proteins, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't",

author = "Z Laron and B Klinger and Jensen, {L T} and B Erster",

year = "1991",

month = aug,

language = "English",

volume = "35",

pages = "145--50",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism

AU - Laron, Z

AU - Klinger, B

AU - Jensen, L T

AU - Erster, B

PY - 1991/8

Y1 - 1991/8

N2 - OBJECTIVE: The purpose of this investigation was to evaluate the effectiveness of short-term administration of recombinant biosynthetic IGF-I on patients with an hereditary inability to generate this hormone.DESIGN AND PATIENTS: Ten patients with Laron type dwarfism (LTD) (4 males, six females) aged 3 1/2 to 37 3/4 years were submitted to seven daily s.c. injections of recombinant IGF-I in doses of 120 or 150 micrograms/kg/day.MEASUREMENTS: Blood samples were drawn before, after three and seven injections, and one week after stopping the trial.RESULTS: The main biochemical and hormonal changes registered were (mean +/- SD): a marked rise in serum type III procollagen (PIIINP) from 4.2 +/- 0.9 to 7.3 +/- 2 micrograms/l (P less than 0.0003) and decrease in the following blood components: plasma hGH from 32.51 +/- 43.77 to 4.02 +/- 2.48 mU/l (P less than 0.001), serum cholesterol from 5.9 +/- 1 to 5.7 +/- 0.8 mmol/l (P less than 0.04), serum SGOT from 28.9 +/- 11.6 to 15.5 +/- 7.6 U/l (P less than 0.01) and serum LDH from 286 +/- 88 to 222 +/- 37 U/l (P less than 0.0005). The response of plasma insulin was variable, decreasing in seven of ten and increasing in three. Some of these effects were transitory, and were found after 3 days therapy but afterwards decreased (insulin, cholesterol and liver tests), others persisted throughout the whole treatment period (hGH, PIINP).CONCLUSIONS: IGF-I mimics the biochemical and hormonal changes described after administration of hGH. The administration of IGF-I in patients with Laron type dwarfism is devoid of side-effects and warrants assessment in long-term studies.

AB - OBJECTIVE: The purpose of this investigation was to evaluate the effectiveness of short-term administration of recombinant biosynthetic IGF-I on patients with an hereditary inability to generate this hormone.DESIGN AND PATIENTS: Ten patients with Laron type dwarfism (LTD) (4 males, six females) aged 3 1/2 to 37 3/4 years were submitted to seven daily s.c. injections of recombinant IGF-I in doses of 120 or 150 micrograms/kg/day.MEASUREMENTS: Blood samples were drawn before, after three and seven injections, and one week after stopping the trial.RESULTS: The main biochemical and hormonal changes registered were (mean +/- SD): a marked rise in serum type III procollagen (PIIINP) from 4.2 +/- 0.9 to 7.3 +/- 2 micrograms/l (P less than 0.0003) and decrease in the following blood components: plasma hGH from 32.51 +/- 43.77 to 4.02 +/- 2.48 mU/l (P less than 0.001), serum cholesterol from 5.9 +/- 1 to 5.7 +/- 0.8 mmol/l (P less than 0.04), serum SGOT from 28.9 +/- 11.6 to 15.5 +/- 7.6 U/l (P less than 0.01) and serum LDH from 286 +/- 88 to 222 +/- 37 U/l (P less than 0.0005). The response of plasma insulin was variable, decreasing in seven of ten and increasing in three. Some of these effects were transitory, and were found after 3 days therapy but afterwards decreased (insulin, cholesterol and liver tests), others persisted throughout the whole treatment period (hGH, PIINP).CONCLUSIONS: IGF-I mimics the biochemical and hormonal changes described after administration of hGH. The administration of IGF-I in patients with Laron type dwarfism is devoid of side-effects and warrants assessment in long-term studies.

KW - Adolescent

KW - Adult

KW - Aspartate Aminotransferases

KW - Child

KW - Child, Preschool

KW - Cholesterol

KW - Dwarfism

KW - Female

KW - Growth Hormone

KW - Humans

KW - Insulin-Like Growth Factor I

KW - L-Lactate Dehydrogenase

KW - Male

KW - Peptide Fragments

KW - Procollagen

KW - Receptors, Somatotropin

KW - Recombinant Proteins

KW - Clinical Trial

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - Journal article

C2 - 1934530

SN - 0300-0664

VL - 35

SP - 145

EP - 150

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 2

ER -

Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism

Abstract

Keywords

Fingerprint

Cite this